Core Viewpoint - The article highlights the evolution of the Chinese scientific instrument industry from 2013 to 2024, emphasizing the role of 12 award-winning entrepreneurs who have driven the industry from a position of following to partial leadership, overcoming foreign monopolies, achieving technological independence, and expanding into global markets [1][2]. Group 1: Breakthrough Phase (2013-2017) - The Chinese scientific instrument industry was characterized as "large but not strong" before 2013, with high-end instruments dominated by foreign companies and local firms primarily producing low-end products [4]. - The first award winner, Li Xiaolou, took bold steps by acquiring the renowned analysis instrument company GBC, demonstrating that local firms could leverage international resources for growth [4][6]. - Huang Zhifang, the second award winner, focused on solidifying his core business during a downturn, leading his company to achieve significant growth and enter the billion-yuan club by emphasizing technology and specialization [6][8]. - The third award winner, Hu Ke, transitioned from scientist to entrepreneur, expanding his company's revenue to 200 million yuan through strategic acquisitions and a global mindset [8][10]. - Liu Zhaogui, the fourth award winner, actively integrated resources through acquisitions, providing a new approach to overcoming technological challenges in the industry [10][12]. - Wang Zhigang, the fifth award winner, enhanced the reputation of domestic instruments by improving product quality and expanding internationally, fostering confidence in local brands [12][14]. Group 2: Domestic Substitution Breakthrough Phase (2018-2021) - The industry entered a critical phase of "domestic substitution" in 2018, driven by escalating trade tensions and a national push for self-sufficiency in high-end scientific instruments [15][16]. - Zhou Zhen, the sixth award winner, exemplified the spirit of relentless technical pursuit, successfully developing high-end mass spectrometers that gained significant market traction [16][18]. - Tang Zhidong, the seventh award winner, innovated within a long-established brand, achieving domestic leadership in electrochemical analysis instruments through a blend of tradition and innovation [18][20]. - Peng Niancai, the eighth award winner, played a crucial role during the COVID-19 pandemic by providing essential diagnostic equipment, significantly enhancing the credibility of domestic instruments [20][22]. - Han Shuanglai, the ninth award winner, rapidly advanced high-end scientific instruments, achieving a 65% increase in new contracts in 2021, demonstrating the potential for accelerated development in the industry [22][24]. Group 3: Intelligent Manufacturing Leading Phase (2022-2024) - The industry entered a high-quality development phase starting in 2022, focusing on integrating digital and physical economies and expanding globally [25][26]. - Dong Qingyun, the tenth award winner, achieved a 37% growth during the pandemic, establishing a strong presence in the particle size testing market and demonstrating the impact of perseverance and innovation [26][28]. - Ding Liangcheng, the eleventh award winner, maintained a focus on core technologies, consistently launching new products that surpassed international standards, promoting a culture of meticulous development [28][30]. - Zhu Xinyong, the twelfth award winner, led his company to become a top domestic brand in ion chromatography, emphasizing the importance of social responsibility and industry development [30][32]. Conclusion - Over the past 12 years, the entrepreneurial spirit in the Chinese scientific instrument industry has evolved through phases of daring exploration, technical perseverance, and global ambition, encapsulated in the principles of persistence, innovation, and responsibility [33][34].

Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new investment company focused on the medical device sector, specifically targeting a stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [1][2] Group 1: Investment Details - Nanjing Pharmaceutical will hold a 59.9% stake in the newly established Nanjing XG South Medicine Medical Device Investment Company, which will focus on acquiring approximately 22.5% of Jiangfeng Biological at a valuation not exceeding 750 million yuan [1][2] - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] Group 2: Strategic Alignment - The establishment of the investment fund is part of Nanjing Pharmaceutical's "14th Five-Year" strategic plan, which emphasizes the integration of health industry development and digital transformation [2] - The investment is expected to enhance the company's core competitiveness while extending its existing industrial chain [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology sector and is recognized as a national high-tech enterprise [3] - The company offers a comprehensive range of products and services, including digital pathology scanning systems and AI-assisted diagnostic systems, positioning it as a leader in the industry [3] - Jiangfeng's strong R&D capabilities and established market presence are expected to complement Nanjing Pharmaceutical's extensive business network and supply chain [3]